Johns Hopkins has been an academic member institution of cooperative groups since the founding of this national oncology research in 1955. Over the decades, our faculties have provided strong clinical and laboratory scientific leadership and administrative leadership to the cooperative groups. Our primary goal is to bring innovative translational science developed in pre-clinical and early phase trials at Johns Hopkins to the National Clinical Trials Network for further development. In conjunction with this, our faculties serve in leadership roles as study chairs and laboratory co-chairs, disease and modality-oriented committee chairs. The majority of our contributions and our longest association has been with ECOG (now ECOG-ACRIN) and secondly, with GOG (now NRG).
The specific aims are: 1) To integrate all of the cooperative group activities within one administrative program at Johns Hopkins to foster a coordinated, collaborative and inclusive process of prioritization of trials and the facilitation of trial activation and accrual. 2) To promote participation in innovatve, multi-modality treatments in cancer with a focus on imaging, radiation, surgery, novel systemic therapeutics and biomarkers. 3) To continue to provide scientific leadership in the NCTN groups and there, disease-oriented committees and promote the involvement of junior faculty. 4) To continue to bring correlative translational research, novel imaging and radiation techniques, cell biology and molecular biology into clinical protocols for all stages of disease. 5) To continue to expand accrual, provide efficient and timely trial activation, and to maintain excellent performance in data quality. These goals will be accomplished through the mission of the Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins. The Center has achieved excellence in translational research with the awarding of six SPORE grants (cervix, Gl-cancer, prostate, breast, lung, head and neck). In addition, early clinical trials of new drugs are conducted under the NCI phase 1 contract (since 1982). The Early Therapeutics Development with Phase II Emphasis grants allows the development of laboratory science and imaging correlative studies. The recent expansion of Center facilities enhances clinical trial accrual.
Johns Hopkins has an extraordinary institutional commitment to the health of the public. Through close collaboration, the Cancer Center and the School of Public Health advance the study of not only cancer treatments, but also the early detection, screening, prevention of cancer and its effect on financial stability and quality of life, thus encompassing the overall impact of cancer on the lives of patients.
|Kalinsky, Kevin; Lee, Sandra; Rubin, Krista M et al. (2017) A phase 2 trial of dasatinib in patients with locally advanced or stage IV mucosal, acral, or vulvovaginal melanoma: A trial of the ECOG-ACRIN Cancer Research Group (E2607). Cancer 123:2688-2697|
|Butterfield, Lisa H; Zhao, Fengmin; Lee, Sandra et al. (2017) Immune Correlates of GM-CSF and Melanoma Peptide Vaccination in a Randomized Trial for the Adjuvant Therapy of Resected High-Risk Melanoma (E4697). Clin Cancer Res 23:5034-5043|
|Chan, John K; Deng, Wei; Higgins, Robert V et al. (2017) A phase II evaluation of brivanib in the treatment of persistent or recurrent carcinoma of the cervix: An NRG Oncology/Gynecologic Oncology Group study. Gynecol Oncol 146:554-559|
|Danilov, Alexey V; Li, Hongli; Press, Oliver W et al. (2017) Feasibility of interim positron emission tomography (PET)-adapted therapy in HIV-positive patients with advanced Hodgkin lymphoma (HL): a sub-analysis of SWOG S0816 Phase 2 trial. Leuk Lymphoma 58:461-465|
|Bernard, Brandon; Muralidhar, Vinayak; Chen, Yu-Hui et al. (2017) Impact of ethnicity on the outcome of men with metastatic, hormone-sensitive prostate cancer. Cancer 123:1536-1544|
|Coleman, Robert L; Brady, Mark F; Herzog, Thomas J et al. (2017) Bevacizumab and paclitaxel-carboplatin chemotherapy and secondary cytoreduction in recurrent, platinum-sensitive ovarian cancer (NRG Oncology/Gynecologic Oncology Group study GOG-0213): a multicentre, open-label, randomised, phase 3 trial. Lancet Oncol 18:779-791|
|Skates, Steven J; Greene, Mark H; Buys, Saundra S et al. (2017) Early Detection of Ovarian Cancer using the Risk of Ovarian Cancer Algorithm with Frequent CA125 Testing in Women at Increased Familial Risk - Combined Results from Two Screening Trials. Clin Cancer Res 23:3628-3637|
|Agarwala, Sanjiv S; Lee, Sandra J; Yip, Waiki et al. (2017) Phase III Randomized Study of 4 Weeks of High-Dose Interferon-?-2b in Stage T2bNO, T3a-bNO, T4a-bNO, and T1-4N1a-2a (microscopic) Melanoma: A Trial of the Eastern Cooperative Oncology Group-American College of Radiology Imaging Network Cancer Research Gro J Clin Oncol 35:885-892|
|Moore, Kathleen N; Tritchler, David; Kaufman, Kenneth M et al. (2017) Genome-wide association study evaluating single-nucleotide polymorphisms and outcomes in patients with advanced stage serous ovarian or primary peritoneal cancer: An NRG Oncology/Gynecologic Oncology Group study. Gynecol Oncol 147:396-401|
|Pili, Roberto; Jegede, Opeyemi; Carducci, Michael A et al. (2017) A Randomized Phase II Study to Determine the Effect of 2 Different Doses of Aflibercept in Patients With Metastatic Renal Cell Carcinoma (ECOG-ACRIN [E4805]). Clin Genitourin Cancer 15:642-651.e1|
Showing the most recent 10 out of 49 publications